Annika S Quinn1, Leticia R Dujardin2, Bridget Knight3, James Benzimra2, Anthony G Quinn2, Bijay Vaidya4,5. 1. West of England Eye Unit, Department of Ophthalmology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, EX2 5DW, UK. annikaquinn@nhs.net. 2. West of England Eye Unit, Department of Ophthalmology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, EX2 5DW, UK. 3. NIHR Exeter Clinical Research Facility, University of Exeter Medical School, University of Exeter, Exeter, UK. 4. Department of Endocrinology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK. 5. University of Exeter Medical School, Exeter, UK.
Abstract
INTRODUCTION: Early diagnosis and treatment of thyroid eye disease (TED) improves outcomes. Previous studies have highlighted delays in diagnosis and referral to specialist centres. The Amsterdam declaration (2009) aimed to halve the time from presentation to diagnosis and from diagnosis to referral to a specialist centre in five years. A recent study from the European group on Graves' orbitopathy tertiary centres showed a trend for earlier referral of patients to the centres. It is unknown whether similar improvements are occurring in secondary care hospitals in the UK. AIM: To study the trend in referral to a UK secondary care specialist TED clinic since the Amsterdam declaration. METHODS: We carried out a prospective audit of patients who attended the specialist TED clinic after the Amsterdam declaration (2010-2015). We compared their clinical characteristics, including duration of symptoms, disease activity and severity, with those of the patients (n = 114) from an earlier audit attending the clinic during 2004-2008. RESULTS: During 2010-2015, 126 patients with TED (97 females, median age 55 years, 39 current smokers) attended the clinic. The median time from onset of symptoms to being seen in the clinic was 5 months, reduced from 12 months in 2004-2008 (p < 0.001). As compared to the 2004-2008 cohort, significantly more patients in the current cohort presented with mild disease (72 vs. 52%, p = 0.002). Twenty-seven per cent patients had active TED (clinical activity score ≥3/7) compared to 18% in 2004-2008 (p = 0.1). CONCLUSIONS: The trend in referral to secondary care specialist TED clinic is changing in line with the Amsterdam declaration aims.
INTRODUCTION: Early diagnosis and treatment of thyroid eye disease (TED) improves outcomes. Previous studies have highlighted delays in diagnosis and referral to specialist centres. The Amsterdam declaration (2009) aimed to halve the time from presentation to diagnosis and from diagnosis to referral to a specialist centre in five years. A recent study from the European group on Graves' orbitopathy tertiary centres showed a trend for earlier referral of patients to the centres. It is unknown whether similar improvements are occurring in secondary care hospitals in the UK. AIM: To study the trend in referral to a UK secondary care specialist TED clinic since the Amsterdam declaration. METHODS: We carried out a prospective audit of patients who attended the specialist TED clinic after the Amsterdam declaration (2010-2015). We compared their clinical characteristics, including duration of symptoms, disease activity and severity, with those of the patients (n = 114) from an earlier audit attending the clinic during 2004-2008. RESULTS: During 2010-2015, 126 patients with TED (97 females, median age 55 years, 39 current smokers) attended the clinic. The median time from onset of symptoms to being seen in the clinic was 5 months, reduced from 12 months in 2004-2008 (p < 0.001). As compared to the 2004-2008 cohort, significantly more patients in the current cohort presented with mild disease (72 vs. 52%, p = 0.002). Twenty-seven per cent patients had active TED (clinical activity score ≥3/7) compared to 18% in 2004-2008 (p = 0.1). CONCLUSIONS: The trend in referral to secondary care specialist TED clinic is changing in line with the Amsterdam declaration aims.
Authors: Mark F Prummel; Annemieke Bakker; Wilmar M Wiersinga; Lelio Baldeschi; Maarten P Mourits; Pat Kendall-Taylor; Petros Perros; Chris Neoh; A Jane Dickinson; John H Lazarus; Carol M Lane; Armin E Heufelder; George J Kahaly; Suzanne Pitz; Jacques Orgiazzi; Alain Hullo; Aldo Pinchera; Claudio Marcocci; Maria S Sartini; Roberto Rocchi; Marco Nardi; Gerry E Krassas; A Halkias Journal: Eur J Endocrinol Date: 2003-05 Impact factor: 6.664
Authors: Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga Journal: Eur J Endocrinol Date: 2008-03 Impact factor: 6.664
Authors: Petros Perros; Colin M Dayan; A Jane Dickinson; Daniel Ezra; Stephanie Estcourt; Peter Foley; Janis Hickey; John H Lazarus; Caroline J MacEwen; Julie McLaren; Geoffrey E Rose; Jimmy Uddin; Bijay Vaidya Journal: Clin Med (Lond) Date: 2015-04 Impact factor: 2.659
Authors: M L Tanda; E Piantanida; L Liparulo; G Veronesi; A Lai; L Sassi; N Pariani; D Gallo; C Azzolini; M Ferrario; L Bartalena Journal: J Clin Endocrinol Metab Date: 2013-02-13 Impact factor: 5.958